GHR and rectal cancer: Yin et al. demonstrated that pegvisomant is more effective than octreotide LAR in suppressing the GH-IGF-1 axis, thus implying that this GH-receptor blocker drug could be effective in treating several types of tumors, such as breast and colon-rectal cancers [18].